Print this page
myeloma
-
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Protocol: 012603Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Protocol: 012603Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials.
Protocol: 022404Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials.
Protocol: 022404Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study.
Protocol: 022404-MM1MDS-A01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study.
Protocol: 022404-MM1MDS-A01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA02Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA02Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy.
Protocol: 022404-MM1OA-S03Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy.
Protocol: 022404-MM1OA-S03Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial).
Protocol: 022404-MM1YA-CTG01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial).
Protocol: 022404-MM1YA-CTG01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other